Minerva神经科学 NERV 深 沪
已收盘 12-19 16:00:00 美东时间
4.04
+0.170
+4.39%
华盛通- 最 高4.07
- 今 开3.845
- 成交量 1.95万股
- 最 低 3.8201
- 昨 收 3.87
- 总市值 2825.33万
- 52周最高 12.46
- 市盈率 静 21.26
- 换手率 0.28%
- 52周最低 1.15
- 委 比 90.13%
- 总股本 699.34万
- 历史最高 126.72
- 量 比 0.51
- 振 幅 6.46%
- 历史最低 1.15
- 每 手 1
- 风险率 0.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Minerva Neurosciences Expands Board Amid Fundraising Effort
Minerva Neurosciences ( ($NERV) ) has shared an update. On November 14, 2025, M...
11-19 21:58
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
Minerva Neurosciences announced the appointment of Dr. Inderjit Kaul as a board member and consultant for the clinical development of roluperidone to treat negative symptoms of schizophrenia. The company recently raised $200 million to fund a confirmatory Phase 3 trial for roluperidone, aiming to address a significant unmet medical need. Dr. Kaul, with extensive experience in schizophrenia drug development, will support Minerva's efforts to advan...
11-19 13:30
Minerva Neurosciences (NERV) Gets a Hold from H.C. Wainwright
H.C. Wainwright analyst Douglas Tsao maintained a Hold rating on Minerva Neuros...
11-10 09:16
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Minerva Neurosciences GAAP EPS of -$0.36
Minerva Neurosciences press release (NERV): Q3 GAAP EPS of -$0.36. Reported a Q3 net loss of $2.74M. More on Minerva Neurosciences Minerva Neurosciences rises on financing of up to $200M to advance Sc...
11-06 01:34
Minerva Neurosciences Q3 EPS $(0.36) Misses $(0.35) Estimate
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. This is a 112.12 percent decrease over earnings of $2.97 per
11-05 20:34
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
Minerva Neurosciences在2025年第三季度完成了8000万美元的私人配售，并计划推进roluperidone的3期临床试验。与FDA达成一致后，公司预计有足够的资金支持NDA重新提交和商业化准备。财务数据显示R&D和管理费用下降，但净损失增加至274.4万美元，现金储备约为1240万美元。
11-05 12:30
Minerva Neurosciences Secures $200M for Drug Trials
The latest update is out from Minerva Neurosciences ( ($NERV) ). On October 21,...
10-22 18:28
Minerva Neurosciences shares are trading higher after the company announced financing of up to $200 million to advance Roluperidone for schizophrenia.
Minerva Neurosciences shares are trading higher after the company announced fin...
10-21 20:03
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
Minerva Neurosciences, Inc. has raised up to $200 million to advance the Phase 3 trial of roluperidone for treating negative symptoms of schizophrenia. The proceeds, including $80 million upfront and additional $80 million via Tranche A warrants, will fund the confirmatory trial and NDA resubmission. Up to $40 million more could be received from Tranche B warrants upon milestone achievements. Three new directors with schizophrenia trial experienc...
10-21 12:00
